Enliven Therapeutics (ELVN) Competitors $20.85 +1.01 (+5.09%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$20.88 +0.03 (+0.14%) As of 08/22/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. CYTK, VKTX, TGTX, KRYS, ACAD, PCVX, AAPG, ACLX, ADMA, and ZLABShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), Arcellx (ACLX), ADMA Biologics (ADMA), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Its Competitors Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Vaxcyte Ascentage Pharma Group International Arcellx ADMA Biologics Zai Lab Enliven Therapeutics (NASDAQ:ELVN) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Is ELVN or CYTK more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -707.17%. Cytokinetics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.15% -27.88% Cytokinetics -707.17%N/A -45.52% Which has higher valuation and earnings, ELVN or CYTK? Enliven Therapeutics has higher earnings, but lower revenue than Cytokinetics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$89.02M-$2.00-10.43Cytokinetics$85.74M53.51-$589.53M-$5.10-7.52 Which has more volatility and risk, ELVN or CYTK? Enliven Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Does the media prefer ELVN or CYTK? In the previous week, Cytokinetics had 3 more articles in the media than Enliven Therapeutics. MarketBeat recorded 15 mentions for Cytokinetics and 12 mentions for Enliven Therapeutics. Cytokinetics' average media sentiment score of 0.78 beat Enliven Therapeutics' score of 0.25 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 8 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ELVN or CYTK? 95.1% of Enliven Therapeutics shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by company insiders. Comparatively, 2.7% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend ELVN or CYTK? Enliven Therapeutics currently has a consensus target price of $41.20, indicating a potential upside of 97.60%. Cytokinetics has a consensus target price of $71.58, indicating a potential upside of 86.71%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Cytokinetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.93 SummaryEnliven Therapeutics beats Cytokinetics on 9 of the 16 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.18B$2.54B$5.75B$9.62BDividend YieldN/A1.57%4.40%4.10%P/E Ratio-10.4322.9131.3026.05Price / SalesN/A554.08432.98193.75Price / CashN/A180.4637.7358.48Price / Book2.535.939.536.61Net Income-$89.02M$31.83M$3.26B$265.65M7 Day Performance3.12%1.89%2.13%2.02%1 Month Performance-6.71%1.33%2.80%-0.31%1 Year Performance-9.35%8.84%30.68%19.06% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.8288 of 5 stars$20.85+5.1%$41.20+97.6%-9.0%$1.18BN/A-10.4350Insider TradeHigh Trading VolumeCYTKCytokinetics3.6135 of 5 stars$38.95+0.7%$71.58+83.8%-31.8%$4.63B$18.47M-7.64250News CoverageVKTXViking Therapeutics3.9933 of 5 stars$42.09+5.1%$86.92+106.5%-59.6%$4.50BN/A-27.5120Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3387 of 5 stars$27.73-1.2%$46.25+66.8%+20.7%$4.46B$454.07M74.95290Positive NewsKRYSKrystal Biotech4.7241 of 5 stars$146.30-2.6%$210.75+44.1%-23.8%$4.35B$359.21M29.74210Trending NewsAnalyst ForecastACADACADIA Pharmaceuticals3.8347 of 5 stars$25.06-1.1%$28.88+15.2%+64.2%$4.27B$1.02B18.84510Insider TradePCVXVaxcyte2.4578 of 5 stars$32.09-1.9%$136.50+325.4%-58.7%$4.25BN/A-7.81160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$47.49+5.6%N/AN/A$4.18B$134.35M0.00600News CoverageACLXArcellx2.1273 of 5 stars$71.82-3.1%$114.31+59.2%+7.3%$4.11B$107.94M-21.0080Positive NewsADMAADMA Biologics4.3876 of 5 stars$17.63+3.8%$27.67+56.9%+1.7%$4.05B$474.17M20.50530Positive NewsZLABZai Lab2.6221 of 5 stars$35.69-0.1%$57.22+60.3%+99.7%$3.97B$398.99M-17.501,869News CoverageInsider Trade Related Companies and Tools Related Companies Cytokinetics Competitors Viking Therapeutics Competitors TG Therapeutics Competitors Krystal Biotech Competitors ACADIA Pharmaceuticals Competitors Vaxcyte Competitors Ascentage Pharma Group International Competitors Arcellx Competitors ADMA Biologics Competitors Zai Lab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access